HolderBook

Sofinnova Investments, Inc.

Reported holdings as of Q2 2026, from 31 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1631134
Reported value
$1.9B
Positions
56
Top 10 weight
58.8%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
NATERA INCNTRA$420.8M1,550,28021.76%+9.97pp31qHELD
VERA THERAPEUTICS INCVERA$119.9M2,793,9876.20%+1.93pp21qHELD
GENMAB A/SGMAB$111.1M4,045,2155.74%+4.98pp2q+437.7%+$90.5M
JAZZ PHARMACEUTICALS PLCJAZZ$88.0M365,3414.55%+0.25pp8q-38.9%-$56.1M
RAPPORT THERAPEUTICS INCRAPP$79.4M1,904,4084.10%+1.84pp9qHELD
SEAPORT THERAPEUTICS INCSPTX$77.4M3,564,8714.00%-newNEW
ULTRAGENYX PHARMACEUTICAL IN CALLRARE$74.0M1,717,5053.83%+1.04pp3q-45.4%-$61.6M
ARRIVENT BIOPHARMA INCAVBP$58.9M1,696,7523.05%+1.56pp10qHELD
BIOAGE LABS INCBIOA$56.2M2,293,7882.91%+1.38pp8qHELD
BRISTOL-MYERS SQUIBB COBMY$50.5M876,9702.61%-1.97pp3q-55.9%-$64.1M
SUPERNUS PHARMACEUTICALSSUPN$48.2M1,036,3282.49%+0.62pp6q+8.6%+$3.8M
RHYTHM PHARMACEUTICALS INCRYTM$45.3M408,0272.34%+0.85pp8q-9.3%-$4.7M
GILEAD SCIENCES INCGILD$43.3M343,1002.24%-newNEW
UNITED THERAPEUTICS CORP DELUTHR$41.4M76,4892.14%-3.27pp5q-52.2%-$45.3M
COGENT BIOSCIENCES INCCOGT$40.1M1,035,1482.07%-1.02pp10q-51.0%-$41.7M
AXSOME THERAPEUTICS INCAXSM$39.3M160,4292.03%-0.62pp9q-24.6%-$12.8M
IMMATICS N.VIMTX$37.2M3,669,3461.92%+0.56pp24q+1.1%+$394.0K
DYNE THERAPEUTICS INCDYN$36.8M1,658,3841.90%+0.78pp13q+1.5%+$543.9K
IMMUNOME INCIMNM$36.5M1,720,3161.88%+0.47pp10q+1.1%+$390.2K
IDEAYA BIOSCIENCES INCIDYA$34.5M925,1191.78%+0.35pp16q-18.3%-$7.7M
ANAPTYSBIO INCANAB$33.3M493,5361.72%+1.20pp7q+98.8%+$16.6M
NEKTAR THERAPEUTICSNKTR$32.9M471,7631.70%+0.31pp4q-7.4%-$2.6M
PHARVARIS N VPHVS$30.5M881,2991.58%+0.70pp11q+7.7%+$2.2M
ARCUS BIOSCIENCES INCRCUS$29.2M945,6901.51%+0.75pp6q+2.4%+$696.9K
INHIBRX BIOSCIENCES INCINBX$28.7M303,1031.48%+0.45pp9q-25.3%-$9.8M
BIOMARIN PHARMACEUTICAL INCBMRN$20.5M358,5681.06%-0.62pp3q-54.1%-$24.2M
VERADERMICS INCMANE$18.3M148,9930.95%+0.77pp2q+103.2%+$9.3M
ALCON AGALC$17.2M255,8240.89%-1.20pp3q-65.0%-$31.8M
INSMED INCINSM$16.9M158,3980.87%-1.28pp10q-54.2%-$20.0M
INTUITIVE SURGICAL INC CALLISRG$15.9Moptions only0.82%-newOPTIONS
GLOBUS MED INC CALLGMED$15.8Moptions only0.82%-newOPTIONS
EDGEWISE THERAPEUTICS INCEWTX$15.5M380,9230.80%+0.34pp9q-1.4%-$226.5K
EXELIXIS INC PUTEXEL$13.8Moptions only0.72%+0.31pp2qOPTIONS
NURIX THERAPEUTICS INCNRIX$12.7M524,0980.66%-newNEW
DESIGN THERAPEUTICS INCDSGN$12.5M865,1350.65%-newNEW
DEFINIUM THERAPEUTICS INCDFTX$12.0M255,9030.62%+0.38pp2q-25.6%-$4.2M
FIRST TRACKS BIOTHERAPEUTICSTRAX$11.4M565,1990.59%-newNEW
ABBOTT LABORATORIESABT$11.2M122,9980.58%-newNEW
DISC MEDICINE INCIRON$10.7M146,2390.55%+0.36pp10q+86.7%+$5.0M
TENAX THERAPEUTICS INCTENX$7.3M500,0390.38%+0.31pp2q+379.0%+$5.8M
SIONNA THERAPEUTICS INCSION$6.4M144,4320.33%-newNEW
ABSCI CORPORATIONABSI$3.9M337,4000.20%-newNEW
MIRUM PHARMACEUTICALS INCMIRM$3.2M27,5910.17%+0.07pp3qHELD
JADE BIOSCIENCES INCJBIO$2.4M107,3910.12%+0.07pp5qHELD
SAVARA INCSVRA$2.2M364,7630.12%+0.04pp13qHELD
PRAXIS PRECISION MEDICINES IPRAX$2.2M6,4400.11%-0.67pp6q-89.9%-$19.2M
SEPTERNA INCSEPN$1.6M47,5060.08%+0.04pp2qHELD
ONKURE THERAPEUTICS INCOKUR$1.5M321,6920.08%+0.05pp2q+127.0%+$820.8K
SAGIMET BIOSCIENCES INCSGMT$1.3M166,6670.07%-newNEW
WAVE LIFE SCIENCES LTDWVE$1.1M189,2530.06%flat5qHELD
AKTIS ONCOLOGY INCAKTS$1.0M32,4360.05%-newNEW
TYRA BIOSCIENCES INCTYRA$1.0M32,2670.05%-0.24pp2q-84.2%-$5.5M
BOLT BIOTHERAPEUTICS INCBOLT$530.2K137,7210.03%+0.01pp5qHELD
NEXTCURE INCNXTC$356.2K222,6540.02%-0.07pp4qHELD
IMAGENEBIO INCIMA$188.1K31,8840.01%flat4qHELD
HEARTFLOW INCHTFL$149.0K5,0790.01%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 71.1%Healthcare Services 21.8%Medical Devices 2.5%Not classified 4.6%
 
SectorValueShare
Biotech & Pharma$1.4B71.1%
Healthcare Services$420.8M21.8%
Medical Devices$49.0M2.5%
Not classified$88.8M4.6%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+14.7%+14.8%-0.1%94%
Q1 2026-0.1%-4.6%+4.5%96%
Q4 2025+36.7%+2.4%+34.4%94%
Q3 2025+22.0%+7.8%+14.1%95%
Q2 2025+8.1%+10.5%-2.4%96%
Q1 2025-10.1%-4.6%-5.5%99%
Q4 2024-9.0%+2.1%-11.1%98%
Q3 2024+4.8%+5.4%-0.6%95%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$1.9B561312172658.8%45
Q1 2026$2.6B692524111650.9%45
Q4 2025$2.3B601123181054.2%44
Q3 2025$1.8B591118221052.0%45
Q2 2025$1.6B581318171751.5%45
Q1 2025$1.5B621819131654.2%45
Q4 2024$1.4B601712201557.8%45
Q3 2024$1.3B581221142960.7%44
Q2 2024$1.9B751831141252.7%40
Q1 2024$1.8B693016142151.4%136
Q4 2023$1.8B601615151365.3%228
Q3 2023$1.6B57191671054.4%45
Q2 2023$1.5B48138131664.8%45
Q1 2023$1.6B51141312964.5%41
Q4 2022$1.7B4651871467.7%45
Q3 2022$1.7B55111881269.0%39
Q2 2022$1.2B561215121563.4%46
Q1 2022$1.3B591212142163.8%46
Q4 2021$1.7B681820112056.7%45
Q3 2021$1.7B702212191961.9%46
Q2 2021$1.7B671716151459.6%47
Q1 2021$1.7B641716161960.0%44
Q4 2020$1.7B661917122163.3%47
Q3 2020$1.3B681813242664.0%44
Q2 2020$1.6B76291891757.6%44
Q1 2020$1.1B64218121666.4%43
Q4 2019$1.4B591014172266.5%45
Q3 2019$1.1B71212161956.1%45
Q2 2019$1.1B69222252059.8%44
Q1 2019$1.0B67188201062.5%45
Q4 2018$802.7M59000060.8%53

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.